Skip to main content
. 2022 Mar;11(3):432–439. doi: 10.21037/tlcr-21-938

Figure 1.

Figure 1

Kaplan-Meier estimates of OS by patient-reported physical function for patients treated with atezolizumab. ACnP, atezolizumab plus carboplatin plus nab-paclitaxel; ACP, atezolizumab plus carboplatin plus paclitaxel; ABCP, atezolizumab plus bevacizumab plus carboplatin plus paclitaxel.